63 research outputs found
Faecal Microbiota Transplantation for the Treatment of Active Ulcerative Colitis
Introduction Ulcerative colitis (UC) is an inflammatory bowel disease that has high rates of persistent or relapsing symptoms despite available therapies. Many of these therapies also have the potential for unacceptable side effects including allergy, intolerance, serious infection and malignancy due to long-term immunosuppression. It is for these reasons that new therapies for UC are required; particularly therapies that target novel pathways and do not suppress the immune system. Faecal microbiota transplantation (FMT) has demonstrated efficacy in the treatment of recurrent and refractory Clostridium difficile infection (CDI) and has been proposed as a novel therapy for UC. Aims The aims of this thesis were to: 1. establish a stool bank of screened donor stool containing viable organisms 2. assess the efficacy and safety of FMT for the induction of remission of UC 3. explore the mechanisms by which FMT may alter the disease process of UC. Methods Methods of stool donor recruitment and screening as well as anaerobic stool processing were developed and optimised. The viability of culturable organisms was validated after 6 months of frozen storage. A double-blind randomised controlled trial of a short duration of FMT using anaerobically prepared stool for the induction of remission of mild to moderate UC was undertaken with clinical and endoscopic remission assessed at 8 weeks and 12 months. Exploratory immunological, microbiological and metabolomic analyses were undertaken. A systematic review and meta-analysis was undertaken to assess the broader evidence for FMT as therapy for the induction of remission of UC. Results A stool bank of anaerobically prepared donor stool was established; 14 (31%) of 44 respondents to donor recruitment questionnaires were eligible. Bacterial viability was similar to baseline at both 2 and 6 months in specimens stored with saline and 10% glycerol and at 2 months in stool stored only in saline, but was reduced by >1 log at 6 months for aerobes, coliforms and lactobacilli in saline alone. In patients undergoing FMT with stool frozen for 2–10 months in 10% glycerol, the cure rate for rCDI was 88% after a single FMT. In mild to moderate active UC, clinical and endoscopic remission was achieved in 12 of the 38 participants (32%) who received pooled donor FMT, compared with 3 of the 35 (9%) who received autologous FMT (odds ratio [OR] 5.0 [95% CI 1.2–20.1]; P = 0.03). A number of bacterial species were associated with the observed donor FMT treatment effect. Neither lamina propria mononuclear cell populations nor short-chain fatty acid levels were associated with the donor FMT treatment effect. Meta-analysis of randomised controlled trials of FMT for UC demonstrated that clinical remission was achieved in 39 of 140 (28%) patients in the donor FMT groups, compared with 13 of 137 (9%) patients in the placebo groups (OR 3.67 [95% CI 1.82– 7.39]; P < 0.01]. Conclusions Establishing a bank of anaerobically prepared frozen donor stool facilitates the delivery of FMT for clinical and clinical trial purposes. Anaerobic stool processing with normal saline and glycerol results in viability of bacteria in frozen storage for 6 months. Donor FMT is an effective therapy for the induction of remission of UC. Further research is required to assess the efficacy and safety of FMT as maintenance therapy for UC and to establish the mechanism of treatment effect.Thesis (Ph.D.) -- University of Adelaide, Adelaide Medical School, 201
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice
Although faecal microbiota transplantation (FMT) has a well-established role in the treatment of recurrent Clostridioides difficile infection (CDI), its widespread dissemination is limited by several obstacles, including lack of dedicated centres, difficulties with donor recruitment and complexities related to regulation and safety monitoring. Given the considerable burden of CDI on global healthcare systems, FMT should be widely available to most centres. Stool banks may guarantee reliable, timely and equitable access to FMT for patients and a traceable workflow that ensures safety and quality of procedures. In this consensus project, FMT experts from Europe, North America and Australia gathered and released statements on the following issues related to the stool banking: general principles, objectives and organisation of the stool bank; selection and screening of donors; collection, preparation and storage of faeces; services and clients; registries, monitoring of outcomes and ethical issues; and the evolving role of FMT in clinical practice, Consensus on each statement was achieved through a Delphi process and then in a plenary face-to-face meeting. For each key issue, the best available evidence was assessed, with the aim of providing guidance for the development of stool banks in order to promote accessibility to FMT in clinical practice.Peer reviewe
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic
The COVID-19 pandemic has led to an exponential
increase in SARS-CoV-
2 infections and associated deaths,
and represents a significant challenge to healthcare
professionals and facilities. Individual countries have
taken several prevention and containment actions to
control the spread of infection, including measures
to guarantee safety of both healthcare professionals
and patients who are at increased risk of infection
from COVID-19. Faecal microbiota transplantation
(FMT) has a well-established
role in the treatment
of Clostridioides difficile infection. In the time of the
pandemic, FMT centres and stool banks are required
to adopt a workflow that continues to ensure reliable
patient access to FMT while maintaining safety and
quality of procedures. In this position paper, based on the
best available evidence, worldwide FMT experts provide
guidance on issues relating to the impact of COVID-19
on FMT, including patient selection, donor recruitment
and selection, stool manufacturing, FMT procedures,
patient follow-up
and research activities
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic
The COVID-19 pandemic has led to an exponential increase in SARS-CoV-2 infections and associated deaths, and represents a significant challenge to healthcare professionals and facilities. Individual countries have taken several prevention and containment actions to control the spread of infection, including measures to guarantee safety of both healthcare professionals and patients who are at increased risk of infection from COVID-19. Faecal microbiota transplantation (FMT) has a well-established role in the treatment of Clostridioides difficile infection. In the time of the pandemic, FMT centres and stool banks are required to adopt a workflow that continues to ensure reliable patient access to FMT while maintaining safety and quality of procedures. In this position paper, based on the best available evidence, worldwide FMT experts provide guidance on issues relating to the impact of COVID-19 on FMT, including patient selection, donor recruitment and selection, stool manufacturing, FMT procedures, patient follow-up and research activities.Peer reviewe
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context
Long noncoding RNAs (lncRNAs) are commonly dys-regulated in tumors, but only a handful are known toplay pathophysiological roles in cancer. We inferredlncRNAs that dysregulate cancer pathways, onco-genes, and tumor suppressors (cancer genes) bymodeling their effects on the activity of transcriptionfactors, RNA-binding proteins, and microRNAs in5,185 TCGA tumors and 1,019 ENCODE assays.Our predictions included hundreds of candidateonco- and tumor-suppressor lncRNAs (cancerlncRNAs) whose somatic alterations account for thedysregulation of dozens of cancer genes and path-ways in each of 14 tumor contexts. To demonstrateproof of concept, we showed that perturbations tar-geting OIP5-AS1 (an inferred tumor suppressor) andTUG1 and WT1-AS (inferred onco-lncRNAs) dysre-gulated cancer genes and altered proliferation ofbreast and gynecologic cancer cells. Our analysis in-dicates that, although most lncRNAs are dysregu-lated in a tumor-specific manner, some, includingOIP5-AS1, TUG1, NEAT1, MEG3, and TSIX, synergis-tically dysregulate cancer pathways in multiple tumorcontexts
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Although theMYConcogene has been implicated incancer, a systematic assessment of alterations ofMYC, related transcription factors, and co-regulatoryproteins, forming the proximal MYC network (PMN),across human cancers is lacking. Using computa-tional approaches, we define genomic and proteo-mic features associated with MYC and the PMNacross the 33 cancers of The Cancer Genome Atlas.Pan-cancer, 28% of all samples had at least one ofthe MYC paralogs amplified. In contrast, the MYCantagonists MGA and MNT were the most frequentlymutated or deleted members, proposing a roleas tumor suppressors.MYCalterations were mutu-ally exclusive withPIK3CA,PTEN,APC,orBRAFalterations, suggesting that MYC is a distinct onco-genic driver. Expression analysis revealed MYC-associated pathways in tumor subtypes, such asimmune response and growth factor signaling; chro-matin, translation, and DNA replication/repair wereconserved pan-cancer. This analysis reveals insightsinto MYC biology and is a reference for biomarkersand therapeutics for cancers with alterations ofMYC or the PMN
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing
molecular features of squamous cell carcinomas (SCCs) from five sites associated with smokin
Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images
Beyond sample curation and basic pathologic characterization, the digitized H&E-stained images
of TCGA samples remain underutilized. To highlight this resource, we present mappings of tumorinfiltrating lymphocytes (TILs) based on H&E images from 13 TCGA tumor types. These TIL
maps are derived through computational staining using a convolutional neural network trained to
classify patches of images. Affinity propagation revealed local spatial structure in TIL patterns and
correlation with overall survival. TIL map structural patterns were grouped using standard
histopathological parameters. These patterns are enriched in particular T cell subpopulations
derived from molecular measures. TIL densities and spatial structure were differentially enriched
among tumor types, immune subtypes, and tumor molecular subtypes, implying that spatial
infiltrate state could reflect particular tumor cell aberration states. Obtaining spatial lymphocytic
patterns linked to the rich genomic characterization of TCGA samples demonstrates one use for
the TCGA image archives with insights into the tumor-immune microenvironment
Why Can't Rodents Vomit? A Comparative Behavioral, Anatomical, and Physiological Study
The vomiting (emetic) reflex is documented in numerous mammalian species, including primates and carnivores, yet laboratory rats and mice appear to lack this response. It is unclear whether these rodents do not vomit because of anatomical constraints (e.g., a relatively long abdominal esophagus) or lack of key neural circuits. Moreover, it is unknown whether laboratory rodents are representative of Rodentia with regards to this reflex. Here we conducted behavioral testing of members of all three major groups of Rodentia; mouse-related (rat, mouse, vole, beaver), Ctenohystrica (guinea pig, nutria), and squirrel-related (mountain beaver) species. Prototypical emetic agents, apomorphine (sc), veratrine (sc), and copper sulfate (ig), failed to produce either retching or vomiting in these species (although other behavioral effects, e.g., locomotion, were noted). These rodents also had anatomical constraints, which could limit the efficiency of vomiting should it be attempted, including reduced muscularity of the diaphragm and stomach geometry that is not well structured for moving contents towards the esophagus compared to species that can vomit (cat, ferret, and musk shrew). Lastly, an in situ brainstem preparation was used to make sensitive measures of mouth, esophagus, and shoulder muscular movements, and phrenic nerve activity-key features of emetic episodes. Laboratory mice and rats failed to display any of the common coordinated actions of these indices after typical emetic stimulation (resiniferatoxin and vagal afferent stimulation) compared to musk shrews. Overall the results suggest that the inability to vomit is a general property of Rodentia and that an absent brainstem neurological component is the most likely cause. The implications of these findings for the utility of rodents as models in the area of emesis research are discussed. © 2013 Horn et al
- …